



- (51) **International Patent Classification:**
C07K 16/28 (2006.01)
- (21) **International Application Number:**
PCT/US2020/016949
- (22) **International Filing Date:**
06 February 2020 (06.02.2020)
- (25) **Filing Language:** English
- (26) **Publication Language:** English
- (30) **Priority Data:**
62/802,161 06 February 2019 (06.02.2019) US
62/889,994 21 August 2019 (21.08.2019) US
- (71) **Applicant:** **PIONYR IMMUNOTHERAPEUTICS, INC.** [US/US]; 2 Tower Place, Suite 800, South San Francisco, CA 94080 (US).
- (72) **Inventors:** **CHAN, Christopher**; c/o Pionyr Immunotherapeutics, Inc., 2 Tower Place, Suite 800, South San Francisco, CA 94080 (US). **PAL, Aritra**; c/o Pionyr Immunotherapeutics, Inc., 2 Tower Place, Suite 800, South San Francisco, CA 94080 (US). **SRIRAM, Venkataraman**; c/o Pionyr


Immunotherapeutics, Inc., 2 Tower Place, Suite 800, South San Francisco, CA 94080 (US). **PRESTA, Leonard, G.**; c/o Pionyr Immunotherapeutics, Inc., 2 Tower Place, Suite 800, South San Francisco, CA 94080 (US). **LE, Tiep, Tu**; c/o Pionyr Immunotherapeutics, Inc., 2 Tower Place, Suite 800, South San Francisco, CA 94080 (US). **LIANG, Linda**; c/o Pionyr Immunotherapeutics, Inc., 2 Tower Place, Suite 800, South San Francisco, CA 94080 (US).

(74) **Agent:** **WIENS, Mayim, E.** et al.; c/o Patent Administrator, Goodwin Procter LLP, 100 Northern Avenue, Boston, MA 02210 (US).

(81) **Designated States** (*unless otherwise indicated, for every kind of national protection available*): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA,

(54) **Title:** ANTI-TREM1 ANTIBODIES AND RELATED METHODS

FIG. 1



(57) **Abstract:** Provided herein are anti-TREM1 antibodies and related methods of making and using anti-TREM1 antibodies. Also provided are methods and compositions for enhancing an immune response and/or for the treatment of an immune-related condition in an individual, e.g., cancer, comprising killing, disabling, or depleting non-stimulatory myeloid cells using an anti-TREM1 antibody or antigen binding fragment thereof.

[Continued on next page]

SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR,
TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

— *of inventorship (Rule 4.17(iv))*

Published:

— *without international search report and to be republished upon receipt of that report (Rule 48.2(g))*